

IRISH JOURNAL OF PSYCHOLOGICAL MEDICINE

VOL 13 NO 4 DECEMBER 1996

ISSN 0790 9667





We don't wish to make
a big scene about your love life...

(But we do think it's worth mentioning!)

DUTONIN

NEFAZODONE

DUTONIN FIRST-LINE IN TREATING DEPRESSION^(1,2)

“...an alternative to SSRIs [Dutonin] may be preferred as a first-line agent
in treating sexually active patients who have depression”⁽¹⁾

Dutonin Prescribing Information (Abbreviated)

Presentation: Tablets containing 100mg and 200mg nefazodone hydrochloride.

Indications: Symptomatic treatment of all types of depressive illness, including depressive syndromes accompanied by anxiety or sleep disturbances. All adverse drug reactions should be reported to the N.D.A.B.

Dosage: Usual therapeutic dose 200mg twice daily.

Range - 200mg - 600mg daily, see data sheet.

Elderly: Usual therapeutic dose 100 - 200mg twice daily.

Renal and Hepatic Impairment: Lower end of dose range.

Children: Not recommended below the age of 18 years.

Contraindications: Hypersensitivity to nefazodone hydrochloride, tablet excipients or other phenylpiperazine antidepressants.

Drug Interactions: With other CNS medication, see data sheet.

Warning/Precautions: Hepatic or renal impairment. Patients at high risk of self

harm should be kept under close supervision during initial treatment phase. Modest decrease in some psychomotor function tests but no impairment of cognitive function. Not recommended in pregnancy and lactation. Use with caution in epilepsy, history of mania/hypomania. No clinical studies available on concurrent use of ECT and nefazodone.

Side Effects: Most frequently asthenia, dry mouth, nausea, somnolence and dizziness; see data sheet.

Overdosage: There is no specific antidote for nefazodone. Gastric lavage recommended for suspected overdosage. Treatment should be symptomatic and supportive in the case of hypotension or excessive sedation.

Product Licence Numbers: Dutonin Tablets 100mg P.A. 2/60/2;

Dutonin Tablets 200mg P.A. 2/60/3.

Product Licence Holder: Bristol-Myers Squibb Pharmaceuticals Limited.

Legal Category: POM Further information from: Medical Information, Bristol-Myers Squibb Pharmaceuticals Ltd., Swords, Co. Dublin.

Telephone: 01-8406244. Date of Preparation: August 1996.

References: (1) Feiger A. et al. "Nefazodone vs Sertraline in Outpatients with major depression: Focus on efficacy, tolerability, and effects on Sexual Function and Satisfaction". J. Clin Psych. 1996; Vol. 57 (suppl. 2): 53-62. (2) Dutonin data sheet, August 1996.



Bristol-Myers Squibb Pharmaceuticals Limited

Swords, Co. Dublin, Ireland.

Tel: (01) 840 6244 Fax: (01) 840 7193

FREEPHONE CUSTOMER SERVICE: 1800 749 749

Editor-in-Chief: Brian Lawlor**Editorial Assistant:** Niamh Gleeson**Advertising Manager:** Frank Corr**Founding Editor:** Mark Hartman**Editors:** Timothy Dinan (London),
David King (Belfast)**Deputy Editor:** Brian O'Shea (Dublin)**Associate Editors:** Ken Brown (Belfast), Patricia Casey (Dublin), Anthony Clare (Dublin), Stephen Cooper (Belfast), Thomas Fahy (Galway), Michael Fitzgerald (Dublin), Michael Kelleher (Cork), Brian Leonard (Galway), Roy McClelland (Belfast), Aidan McGennis (Dublin), Ciaran O'Boyle (Dublin), Eadbhard O'Callaghan (Dublin), Art O'Connor (Dublin), Eithna O'Gorman (Belfast), Ian Pullen (Edinburgh), David Sheehan (Tampa), Philip Snaith (Leeds), Hugh Staunton (Dublin), John Waddington (Dublin), Richard Williams (Calgary)**Statistical Editor:** Leslie Daly (Dublin)**Deputy Statistical Editor:** Ronan Conroy (Dublin)**Submissions & correspondence to:**
The Editor,
Irish Journal of Psychological Medicine,
99 Upper George's Street,
Dun Laoghaire,
Co Dublin.**Telephone**

01-2803967; Int: +353-1-2803967

Fax

01-2807076; Int: +353-1-2807076

PublisherMedMedia Ltd.
Media House,
99 Upper George's Street,
Dun Laoghaire,
Co Dublin.**Printing:** New Cityview Press**Subscriptions**Rates per volume of four issues
(Mar, Jun, Sept, Dec)
STG£43 EU, US\$96 USA, STG£53
elsewhere (single issues US\$28 USA,
STG£13.25 elsewhere) incl. airmail
postage internationally.**Subscription enquiries, orders
and cheques made payable to:**Royal Society of Medicine Press Ltd.,
1 Wimpole St,
London, W1M 8AE, UK.
Tel: 0171-2902927;
int: +44-171-2902927.
Fax: 0171-2902929;
int: +44-171-2902929.**Circulation**3,000 to 54 countries.
Journal participates in the World Health
Organisation project to improve
distribution of scientific materials on
mental health.Publication does not imply
endorsement. Limited photocopying
authorisation granted for a fee to
Copyright Clearance Center,
27 Congress Street, Salem, MA 01970,
USA, or to appropriate Reproduction
Rights Organisation; isolated non-profit,
academic photocopying excepted.**EDITORIAL****130 Liaison psychiatry**

John Sheehan

ORIGINAL PAPERS**132 A comparison of voluntary and involuntary patients admitted to hospital**

Siobhan Rooney, Kieran C Murphy, Fiona Mulvaney, Eadbhard O'Callaghan, Conall Larkin

138 Schizophrenia, lung cancer and glutathione-S-transferase- μ

Kieran C Murphy, M Graham, T Mantle, RK Shelley

140 Controlled assessment of alcoholics admitted involuntarily to a general psychiatric hospital

Fionnula O'Loughlin, Marcus Webb

BRIEF REPORTS**144 Screening for depression in hospitalised elderly medical patients**

Barbara Farragher, Margo Wrigley, Orla Donohoe, Joseph Duggan

147 Suicide in Kerry: a comparison of the official and a clinically based rate

Mary Naughton, Anne Doyle, Patrick Melia, Don Barry

AUDITS**149 Admissions to a day hospital and to a general hospital psychiatric unit in a new community psychiatric service**

Anil P Joseph, Ruth Loane, John Sheehan

REVIEWS**151 Recent developments in the genetics of schizophrenia**

Kieran C Murphy, Michael Gill

155 The molecular genetics of affective disorders: An overview

Lesley A Mynett-Johnson, Patrick McKeon

PERSPECTIVE**162 Suicide: Some ethical implications**

Michael J Kelleher

CASE REPORTS**164 Two cases of transvestophilia arising following behavioural psychotherapy treatment of obsessive compulsive disorder**

S Rani, Lynne Drummond

166 Schizophrenia in a patient with established Gilles de la Tourette Syndrome

Elizabeth C Cassidy, Steven John Miller, Julie F Chalmers

168 Asymptomatic tricyclic toxicity associated with diltiazem

Paul A Cotter, Peter W Raven, Marina Hudson

131 Guidelines for authors**160 John Dunne Medal****170 Letters to the Editor****172 Index to key words 1996****174 Index to authors 1996****Cover illustration:** 'The Cottage Garden', Walter Osbourne (1859-1903)

Indexed and abstracted by BIOLOGICAL ABSTRACTS (BIOSIS Previews); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE/INIST; PASCAL; EXCERPTA MEDICA/EMBASE; INSTITUTE FOR SCIENTIFIC INFORMATION; CURRENT CONTENTS/Social & Behavioural Sciences (Social Science CITATION INDEX, Research Alert); PSYCHOLOGICAL ABSTRACTS (PsycINFO/PsycLIT); Cumulative Index to Nursing & Allied Health Literature, Current AIDS Literature (CAB Abstracts), International Pharmaceutical Abstracts, Linguistics & Language Behaviour Abstracts, Nutrition Abstracts and Reviews, (CAB Abstracts), Referativnyi Zhurnal, Social Planning/Policy & Development Abstracts, Social Work Research & Abstracts, Sociological Abstracts.


Microfilm, microfiche & article copies from University Microfilms International, 300 North Zeeb Rd., Ann Arbor, MI 48106, USA. Journal included in the Adonis service, whereby article copies can be printed out from compact disks (CD-ROM) on demand; explanatory leaflet available from ADONIS BV, PO Box 639, 1000 AV Amsterdam, The Netherlands. Journal listed in Ulrich's International Periodicals Directory (Bowker International Serials Database), EBSCO's Selected Periodicals for the Medical and Health Sciences, & EBSCO's Librarians' Handbook.

REASON TO BE CHEERFUL



LUSTRAL™ 50mg

sertraline



Established in treating depression



Abbreviated Prescribing Information:
LUSTRAL™ (sertraline)

Presentation: Tablets containing 50mg or 100mg sertraline. **Indications:** Treatment of symptoms of depressive illness, including accompanying symptoms of anxiety. Prevention of relapse or recurrence of depressive episodes, including accompanying symptoms of anxiety. Obsessive compulsive disorder (OCD). **Dosage:** Lustral should be given as a single daily dose. The initial dose is 50mg and the usual antidepressant dose

is 50mg. Dosage can be further increased, if appropriate, to a maximum of 200mg daily. Patients should be maintained on the lowest effective dose. *Use in children:* Not recommended. *Use in the elderly:* Usual adult dose. **Contra-indications:** Hypersensitivity to this group of drugs. Hepatic insufficiency, unstable epilepsy and convulsant disorders, pregnancy and lactation. Do not

use with, or within two weeks of ending treatment with, MAOI's. At least 14 days should elapse before starting any MAOI following discontinuation of Lustral. **Precautions, Warnings:** Renal insufficiency, ECT, epilepsy, driving. Lustral should be discontinued in a patient who develops seizures. Lustral should not be administered with benzodiazepines or other tranquilizers in patients who drive or operate machinery. The patient should be monitored for signs of suicide or mania. **Drug Interactions:** Caution with other centrally active medication. Serotonergic drugs such as tryptophan or fenfluramine should not be used with Lustral. Lithium levels should be monitored. Although Lustral has been shown to have no adverse interaction with alcohol, concomitant use with alcohol is not recommended. The potential for Lustral to interact with other highly protein bound drugs should be borne in mind. Interactions with e.g. warfarin, diazepam, tolbutamide and cimetidine have not been fully assessed. With warfarin prothrombin time should be monitored when Lustral is initiated or stopped. **Side effects:** Dry mouth, nausea, diarrhoea/loose stools, ejaculatory delay, tremor, increased sweating,

dizziness, insomnia, somnolence, headache and dyspepsia. Rarely, abnormal LFTs, hyponatraemia. The following have been reported with Lustral but may have no causal relationship: movement disorders, convulsions, menstrual irregularities, hyperprolactinaemia, galactorrhoea and rash. As with other serotonin re-uptake inhibitors rare reports of agitation, confusion, depersonalisation, hallucinations, nervousness, postural hypotension, hypo/hypertension, tachycardia and arrhythmias. As with all psychoactive medicines, possible side effects on discontinuation, such as dizziness, sensory disturbance, sleep disturbance, agitation or anxiety, nausea and sweating. **Legal Category:** S1A. **Package Quantities:** 50mg tablet (PA 19/46/4) Calendar pack of 28; 100mg tablet (PA 19/46/5) Calendar pack of 28. **Product Authorisation Holder:** Pfizer Limited, Sandwich, Kent.

Further information on request: Pfizer (Ireland) Limited, Pharmapark, Chapelizod, Dublin 20, Republic of Ireland.

